▎WuXiEdited by Kant Content Team

Recently, Bristol Myers Squibb announced the latest topline results from the EMERGENT-4 and EMERGENT-5 open-label Phase 3 clinical trials. The analysis shows,Adult patients with schizophrenia inSymptom improvement was sustained with Cobenfy (xanomeline and trospium chloride, i.e., KarXT) oral capsules treatment for up to 52 weeks, indicating the durability of efficacy.It is worth mentioning that,CobenfyAt the beginning of this year, it was reported by the industry mediaEvaluate: 10 Drugs Expected to Be Approved in 2024Potential blockbuster therapyOne of.

52-Week Open-Label EMERGENT-4 Trial Results

EMERGENT-4Is a 52-week Phase 3 outpatient open-label extension study, evaluated the long-term safety, tolerability, and efficacy of Cobenfy in 156 adult patients with schizophrenia who had previously completed treatment in EMERGENT-2 or EMERGENT-3 (a 5-week double-blind placebo-controlled study of efficacy and safety).

During the 52-week trial period,Cobenfy treatment led to sustained improvements in schizophrenia symptoms across all efficacy measures, including the Positive and Negative Syndrome Scale (PANSS) total score, Clinical Global Impression-Severity (CGI-S), PANSS positive subscale, and PANSS negative subscale scores.Subjects who received placebo in the acute trial experienced rapid improvement in symptoms after starting Cobenfy. Schizophrenia symptoms continued to improve throughout the 52-week study, regardless of whether subjects received Cobenfy or placebo in the acute trial.At the end of the trial, 69% of the patients who completed the studySymptoms of Schizophrenia andCompared to the acute test baseline,Achieve ≥30% improvement (based on PANSS total score measurement).

Results of the 52-Week Open-Label EMERGENT-5 Trial

EMERGENT-5 is a 52-week Phase 3 outpatient open-label study designed to evaluate the long-term safety, tolerability, and efficacy of Cobenfy in 566 adult patients with schizophrenia whose symptoms were stabilized on previous antipsychotic medications and who had not previously received Cobenfy. The trial enrolled patients with a PANSS total score ≤80 (mean 66.0) and a CGI-S score ≤4 (mean 3.4), considered to have mild to moderate illness.

Analysis showed that after receiving Cobenfy treatment, patients' schizophrenia symptoms improved across all efficacy endpoints, including PANSS total score, CGI-S, PANSS positive subscale, and PANSS negative subscale scores at 52 weeks, confirming that long-term treatment can maintain efficacy.At Week 52, 30% of subjects had a ≥30% reduction in PANSS total score from baseline, with an average decrease of -5.5 points from baseline.

Qualitative interviews in the trial found that,Most patients receiving Cobenfy in the EMERGENT-5 long-term trial reported improvements in quality of life across physical, social, emotional, and role functioning.

In two 52-week trials, Cobenfy was generally well-tolerated, with side effects consistent with previous trial results for Cobenfy.

CobenfyComposed of two active ingredients, xanomeline and trospium chloride, it aims to activate muscarinic acetylcholine receptors in the brain while reducing effects on peripheral muscarinic acetylcholine receptors.By stimulating muscarinic receptors M1 and M4, xanomeline can alleviate negative symptoms such as apathy, reduced social drive, enhance cognitive abilities, and is highly beneficial for improving other psychiatric symptoms like hallucinations and delusions.The quaternary ammonium compound trospium chloride is a muscarinic receptor antagonist that can inhibit the side effects of xanomeline in peripheral nerves.

The U.S. FDA in September this yearApprovalCobenfyOral capsules are used to treat adult patients with schizophrenia.The FDA press release pointed out that this is a targetedThe First Antipsychotic Drug Targeting Cholinergic Receptors，For a long timeSchizophreniaStandard therapy targets dopamine receptors.This therapy also marksThe first new mechanism drug for treating schizophrenia in decades.